Literature DB >> 11241462

Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine.

H Sormunen1, M Stenvik, J Eskola, T Hovi.   

Abstract

Antibody responses were studied in five groups of children immunized with different three-dose schedules of inactivated poliovirus vaccine (IPV). The age of the child at the first dose (1-4 months) and the interval between the first and second doses (2-4 months) influenced the initial responses in a serotype-dependent manner. All the groups attained sufficient antibody level after three doses but the third dose given at 18 months resulted in higher persisting antibody levels than that given at 12 months. The highest persisting antibody titers against PV1 and PV2 (but not against PV3) at the age of 3 years were measured in the control group immunized with the current schedule (P < 0.001) in which the first dose is given at 6 months. The level of maternal antibodies present at the time of the first dose correlated negatively with the antibody titers as late as at 3 years of age. It is concluded that three doses of IPV given in widely variable schedules may result in satisfactory immune responses in children but, for optimal results, very early onset of the program and short dosage intervals should be avoided.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241462     DOI: 10.1002/1096-9071(200104)63:4<305::aid-jmv1006>3.0.co;2-u

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies.

Authors:  Dhohyung Kim; Devra Huey; Michael Oglesbee; Stefan Niewiesk
Journal:  Blood       Date:  2011-02-28       Impact factor: 22.113

2.  Preeradication vaccine policy options for poliovirus infection and disease control.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi
Journal:  Risk Anal       Date:  2013-03-05       Impact factor: 4.000

Review 3.  Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies.

Authors:  Stefan Niewiesk
Journal:  Front Immunol       Date:  2014-09-16       Impact factor: 7.561

4.  Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.

Authors:  Jakob P Cramer; José Jimeno; Htay Htay Han; Stella Lin; Katharina Hartmann; Astrid Borkowski; Xavier Sáez-Llorens
Journal:  Vaccine       Date:  2020-06-17       Impact factor: 3.641

Review 5.  Vaccines for Perinatal and Congenital Infections-How Close Are We?

Authors:  Tulika Singh; Claire E Otero; Katherine Li; Sarah M Valencia; Ashley N Nelson; Sallie R Permar
Journal:  Front Pediatr       Date:  2020-12-15       Impact factor: 3.418

6.  Safety, Immunogenicity and Lot-to-Lot Consistency of Sabin-Strain Inactivated Poliovirus Vaccine in 2-Month-Old Infants: A Double-Blind, Randomized Phase III Trial.

Authors:  Yan Zheng; Zhifang Ying; Yanxiang Zou; Taotao Zhu; Dinggu Qian; Weixiao Han; Ya Jiang; Zhiwei Jiang; Xingyan Li; Jianfeng Wang; Jin Lei; Li Xu; Deyu Jiang; Changgui Li; Xiaoqiang Liu
Journal:  Vaccines (Basel)       Date:  2022-02-08

7.  Synergistic induction of interferon α through TLR-3 and TLR-9 agonists identifies CD21 as interferon α receptor for the B cell response.

Authors:  Dhohyung Kim; Stefan Niewiesk
Journal:  PLoS Pathog       Date:  2013-03-14       Impact factor: 6.823

8.  Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame.

Authors:  James T Gaensbauer; Chris Gast; Ananda S Bandyopadhyay; Miguel O'Ryan; Xavier Saez-Llorens; Luis Rivera; Eduardo Lopez-Medina; Mario Melgar; William C Weldon; M Steven Oberste; Ricardo Rüttimann; Ralf Clemens; Edwin J Asturias
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

Review 9.  Cooperation of Oligodeoxynucleotides and Synthetic Molecules as Enhanced Immune Modulators.

Authors:  Shireen Nigar; Takeshi Shimosato
Journal:  Front Nutr       Date:  2019-08-27

10.  Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?

Authors:  Sonia Resik; Alina Tejeda; Ondrej Mach; Magile Fonseca; Manuel Diaz; Nilda Alemany; Lai Heng Hung; Yoan Aleman; Ileana Mesa; Gloria Garcia; Roland W Sutter
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.